Literature DB >> 26222340

Different Profile of Efficacy of Thiopurines in Ulcerative Colitis and Crohn's Disease.

Antonio Rispo1, Anna Testa, Giovanni Domenico De Palma, Sara Donetto, Maria Diaferia, Dario Musto, Olga Nardone, Francesco Maione, Nicola Caporaso, Fabiana Castiglione.   

Abstract

BACKGROUND: Thiopurines are effective drugs in treating ulcerative colitis (UC) and Crohn's disease (CD) even if studies that specifically investigate these drugs' profile of efficacy in UC compared with CD are scarce. Our aim was to compare the profile of efficacy of thiopurines in patients with UC and CD.
METHODS: We perfomed a longitudinal observational study evaluating steroid-free clinical remission (CR) and mucosal healing (MH) in all patients with UC and CD who would complete 2 years of maintenance treatment with thiopurines. In patients with UC, CR and MH were assessed before starting treatment and 2 years later using the Mayo score (CR = Mayo score <2; MH = Mayo subscore ≤1). In patients with CD, CR and MH were assessed at the same time points using the Crohn's disease activity index (CR = Crohn's disease activity index < 150) and the Simplified Endoscopic Score for Crohn's Disease (MH = Simplified Endoscopic Score for Crohn's Disease < 2). The efficacy of thiopurines was assessed through intention-to-treat and per-protocol analyses.
RESULTS: The study included 205 steroid-dependent patients (104 UC; 101 CD), 140 of whom (70 UC; 70 CD) completed the 2-year observation period. Steroid-free CR was recorded in 43 patients with UC and 37 with CD (intention-to-treat: 41% versus 36%; P = 0.6; per-protocol: 61% versus 53%; P = 0.4); MH was obtained in 38 patients with UC and 17 with CD (intention-to-treat: 36% versus 16%; P < 0.01; odds ratio, 2.9; per-protocol: 54% versus 25%; P < 0.01; odds ratio, 3.7).
CONCLUSIONS: Thiopurines are effective in maintaining steroid-free CR in both UC and CD although they show a better profile of efficacy in terms of MH in cases of UC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26222340     DOI: 10.1097/MIB.0000000000000538

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

1.  Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.

Authors:  Marcello Cintolo; Giuseppe Costantino; Socrate Pallio; Walter Fries
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

2.  More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.

Authors:  Mark M T J Broekman; Marieke J H Coenen; Corine J van Marrewijk; Geert J A Wanten; Dennis R Wong; Andre L M Verbeek; Olaf H Klungel; Piet M Hooymans; Henk-Jan Guchelaar; Hans Scheffer; Luc J J Derijks; Dirk J de Jong
Journal:  Inflamm Bowel Dis       Date:  2017-10       Impact factor: 5.325

3.  A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease.

Authors:  Arno R Bourgonje; Julius Z H von Martels; Ruben Y Gabriëls; Tjasso Blokzijl; Manon Buist-Homan; Janette Heegsma; Bernadien H Jansen; Hendrik M van Dullemen; Eleonora A M Festen; Rinze W F Ter Steege; Marijn C Visschedijk; Rinse K Weersma; Paul de Vos; Klaas Nico Faber; Gerard Dijkstra
Journal:  Front Med (Lausanne)       Date:  2019-11-05

Review 4.  A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation.

Authors:  Masahiro Kishi; Fumihito Hirai; Noritaka Takatsu; Takashi Hisabe; Yasumichi Takada; Tsuyoshi Beppu; Ken Takeuchi; Makoto Naganuma; Kazuo Ohtsuka; Kenji Watanabe; Takayuki Matsumoto; Motohiro Esaki; Kazutaka Koganei; Akira Sugita; Keisuke Hata; Kitarou Futami; Yoichi Ajioka; Hiroshi Tanabe; Akinori Iwashita; Hirotaka Shimizu; Katsuhiro Arai; Yasuo Suzuki; Tadakazu Hisamatsu
Journal:  J Gastroenterol       Date:  2022-03-02       Impact factor: 7.527

5.  Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice.

Authors:  Prathima Anandi; Alyson L Dickson; QiPing Feng; Wei-Qi Wei; William D Dupont; Dale Plummer; Ge Liu; Rany Octaria; Katherine A Barker; Vivian K Kawai; Kelly Birdwell; Nancy J Cox; Adriana Hung; C Michael Stein; Cecilia P Chung
Journal:  Pharmacogenomics J       Date:  2020-02-14       Impact factor: 3.245

6.  Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity.

Authors:  Takato Maeda; Hirotake Sakuraba; Hiroto Hiraga; Shukuko Yoshida; Yoichi Kakuta; Hidezumi Kikuchi; Shogo Kawaguchi; Keisuke Hasui; Tetsuya Tatsuta; Daisuke Chinda; Tatsuya Mikami; Shinsaku Fukuda
Journal:  Intest Res       Date:  2021-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.